Recent Updates
Recently added Catalysts
AGIO

Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2015 Financial Results on May 7, 2015

Key Takeaway: CAMBRIDGE, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Thursday, May 7,

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+80%
120-day peak, hindsight
Typical move
5%
average across 13 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
Mitapivat
Phase 3 · Transfusion-dependent Alpha-Thalassemia

Full Press Release Details

CAMBRIDGE, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2015 at 8:30 a.m. EDT to report its first quarter 2015 financial results and discuss recent clinical development and corporate activities.
The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 29316015. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging its knowledge of metabolism, biology and genomics. For more information, please visit the company's website at agios.com.
Last updated: Apr 28, 2015